ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,695,084 | -5.4% | 81,338 | +8.7% | 0.00% | 0.0% |
| Q2 2023 | $1,792,490 | +24.2% | 74,819 | -2.4% | 0.00% | +33.3% |
| Q1 2023 | $1,442,986 | +49.2% | 76,673 | +26.2% | 0.00% | 0.0% |
| Q4 2022 | $967,188 | -1.3% | 60,753 | +1.4% | 0.00% | 0.0% |
| Q3 2022 | $980,000 | +51.7% | 59,909 | +30.6% | 0.00% | +50.0% |
| Q2 2022 | $646,000 | +11.8% | 45,877 | +91.9% | 0.00% | +100.0% |
| Q1 2022 | $578,000 | +99.3% | 23,906 | +92.3% | 0.00% | 0.0% |
| Q4 2021 | $290,000 | +42.2% | 12,429 | +1.1% | 0.00% | 0.0% |
| Q3 2021 | $204,000 | -20.9% | 12,290 | +16.6% | 0.00% | 0.0% |
| Q2 2021 | $258,000 | -42.7% | 10,540 | +25.2% | 0.00% | -50.0% |
| Q4 2020 | $450,000 | +35.1% | 8,418 | +4.1% | 0.00% | 0.0% |
| Q3 2020 | $333,000 | -5.4% | 8,086 | +11.1% | 0.00% | 0.0% |
| Q2 2020 | $352,000 | – | 7,278 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |